Cargando…

Development of a ferritin-based nanoparticle vaccine against the SARS-CoV-2 Omicron variant

Detalles Bibliográficos
Autores principales:	Tai, Wanbo, Chai, Benjie, Feng, Shengyong, Zhuang, Xinyu, Ma, Jun, Pang, Mujia, Pan, Lin, Yang, Zi, Tian, Mingyao, Cheng, Gong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157036/ https://www.ncbi.nlm.nih.gov/pubmed/35650183 http://dx.doi.org/10.1038/s41392-022-01041-8

Ejemplares similares

An mRNA-based T-cell-inducing antigen strengthens COVID-19 vaccine against SARS-CoV-2 variants
por: Tai, Wanbo, et al.
Publicado: (2023)

T-cell immunity: a barrier to Omicron immune evasion
por: Yu, Fei, et al.
Publicado: (2022)

RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge
por: Shi, Juan, et al.
Publicado: (2022)

A decoy microrobot that removes SARS-CoV-2 and its variants in wastewater
por: Lai, Jialin, et al.
Publicado: (2022)

Identification of Entry Inhibitors against Delta and Omicron Variants of SARS-CoV-2
por: Lee, Richard Kuan-Lin, et al.
Publicado: (2022)

Ad26.COV2.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaques
por: Yu, Jingyou, et al.
Publicado: (2023)

Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants
por: Liu, Yubin, et al.
Publicado: (2023)

SARS‐CoV‐2 Omicron variant: Characteristics and prevention
por: He, Xuemei, et al.
Publicado: (2021)

Why is the SARS-CoV-2 Omicron variant milder?
por: Xia, Bingqing, et al.
Publicado: (2022)

Importation of SARS-CoV-2 Omicron variant in Beijing, China
por: Li, Fu, et al.
Publicado: (2022)

Inhalation delivery of dexamethasone with iSEND nanoparticles attenuates the COVID-19 cytokine storm in mice and nonhuman primates
por: Meng, Qian-Fang, et al.
Publicado: (2023)

A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection
por: Shi, Juan, et al.
Publicado: (2022)

Severe hemolytic exacerbations of Chinese PNH patients infected SARS‐CoV‐2 Omicron
por: Yang, Hui, et al.
Publicado: (2023)

SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity
por: Joyce, M. Gordon, et al.
Publicado: (2021)

SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity
por: Joyce, M. Gordon, et al.
Publicado: (2021)

Monovalent vaccination with inactivated SARS-CoV-2 BA.5 protects hamsters against Omicron but not non-Omicron variants
por: Ong, Chon Phin, et al.
Publicado: (2023)

Omicron variant in the current SARS-CoV-2 pandemic
por: Nasiri, Kaveh, et al.
Publicado: (2022)

The mysterious origins of the Omicron variant of SARS-CoV-2
por: Du, Pei, et al.
Publicado: (2022)

Plasma Neutralization of the SARS-CoV-2 Omicron Variant
por: Schmidt, Fabian, et al.
Publicado: (2021)

Is Omicron the last SARS-CoV-2 Variant of Concern?
por: Rahimi, Farid, et al.
Publicado: (2022)

Is the Omicron variant of SARS-CoV-2 coming to an end?
por: Zhao, Yingjie, et al.
Publicado: (2022)

Neutralization and Stability of SARS-CoV-2 Omicron Variant
por: Zeng, Cong, et al.
Publicado: (2021)

Recent insights into SARS‐CoV‐2 omicron variant
por: da Silva, Severino Jefferson Ribeiro, et al.
Publicado: (2022)

Omicron variants of SARS-CoV-2 and long COVID
por: Yang, Chengliang, et al.
Publicado: (2022)

Determinants of reinfection with SARS-CoV-2 Omicron variant
por: Bisharat, N., et al.
Publicado: (2023)

A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge
por: Wuertz, Kathryn McGuckin, et al.
Publicado: (2021)

Doxorubicin loaded ferritin nanoparticles for ferroptosis enhanced targeted killing of cancer cells
por: Yang, Runlin, et al.
Publicado: (2019)

Difference of Clinical Characteristics in Patients with Omicron and Delta Variants of SARS-CoV-2 in Beijing, China
por: Tian, Di, et al.
Publicado: (2023)

Innate immune imprints in SARS-CoV-2 Omicron variant infection convalescents
por: Li, Zhiqing, et al.
Publicado: (2022)

Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant
por: Yamasoba, Daichi, et al.
Publicado: (2023)

564. SARS-CoV-2 Ferritin Nanoparticle Vaccines Elicit Broad SARS Coronavirus Immunogenicity
por: Joyce, M G, et al.
Publicado: (2021)

In silico design of refined ferritin-SARS-CoV-2 glyco-RBD nanoparticle vaccine
por: Masoomi Nomandan, Seyedeh Zeinab, et al.
Publicado: (2022)

Role of Omicron variant of SARS-CoV-2 in children in Germany
por: Bittmann, Stefan
Publicado: (2022)

Structural Analysis of the SARS-CoV-2 Omicron Variant Proteins
por: Yang, Qiangzhen, et al.
Publicado: (2021)

Omicron: A highly transmissible SARS-CoV-2 variant
por: Rahimi, Farid, et al.
Publicado: (2022)

Challenges of SARS-CoV-2 Omicron Variant and appropriate countermeasures
por: Shao, Wenxia, et al.
Publicado: (2022)

High rate of reinfection with the SARS-CoV-2 Omicron variant
por: Nguyen, Nhu Ngoc, et al.
Publicado: (2022)

Genomic Perspectives on the Emerging SARS-CoV-2 Omicron Variant
por: Ma, Wentai, et al.
Publicado: (2022)

SARS-CoV-2 Evolution: On the Sudden Appearance of the Omicron Variant
por: Berkhout, Ben, et al.
Publicado: (2022)

Insights on the mutational landscape of the SARS-CoV-2 Omicron variant
por: Miller, Nathaniel L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hg0eokrmj870hr53v39u1agdgv